Immunome公司宣布,其药物Varegacestat在临床试验中取得了积极成果。数据显示,该疗法不仅在主要疗效终点上实现了统计学意义的显著改善,而且在所有预先设定的关键次要疗效终点上也同样观察到了具有统计学意义的积极变化。这一结果标志着该候选药物在相关治疗领域取得了重要进展。
Immunome公司宣布,其药物Varegacestat在临床试验中取得了积极成果。数据显示,该疗法不仅在主要疗效终点上实现了统计学意义的显著改善,而且在所有预先设定的关键次要疗效终点上也同样观察到了具有统计学意义的积极变化。这一结果标志着该候选药物在相关治疗领域取得了重要进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.